Important Notice for GSK plc ADR Holders: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
NEW YORK, March 21, 2025 – Rosen Law Firm, a global investor rights law firm, alerts purchasers of American Depositary Receipts (ADRs) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025 lead plaintiff deadline. The lawsuit seeks to recover damages for GSK plc investors under the Securities Exchange Act of 1934.
Background
GSK plc is a global healthcare company that researches, develops, manufactures, and sells pharmaceutical medicines, vaccines, and consumer healthcare products. The company operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Allegations
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the company’s business, operational, and compliance policies. Specifically, the defendants allegedly failed to disclose that:
- GSK plc was failing to report safety data regarding its Zofran medication, which is used to treat nausea and vomiting in pregnant women;
- GSK plc was under investigation by regulatory authorities for its marketing practices related to Zofran;
- GSK plc was experiencing declining sales for certain of its products, including its respiratory medications Seretide and Advair;
- GSK plc was experiencing manufacturing issues at its plant in Montrose, UK.
Impact on Individual Investors
If you purchased GSK plc ADRs during the Class Period, you may be eligible to join the action as a lead plaintiff. The lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, please contact Rosen Law Firm before the lead plaintiff deadline. Your ability to share in any recovery doesn’t require you to serve as a lead plaintiff.
Impact on the World
The lawsuit against GSK plc is part of a larger trend of pharmaceutical companies facing increased scrutiny over their marketing and safety practices. The case highlights the importance of transparency in the pharmaceutical industry and the need for companies to disclose material information to investors in a timely and accurate manner. The outcome of this lawsuit could set a precedent for future cases and potentially lead to increased regulation of the industry.
Conclusion
Rosen Law Firm encourages investors who purchased GSK plc ADRs during the Class Period to contact the firm before the lead plaintiff deadline to discuss their potential role in this litigation. The firm represents investors worldwide, and it has a proven track record of securing significant recoveries for investors.
About Rosen Law Firm: Rosen Law Firm is a global investor rights law firm committed to protecting investors and securing financial compensation for investors who have been victims of securities fraud, negligence, or other forms of corporate wrongdoing. The law firm represents investors throughout the world, focusing its practice on securities class actions and shareholder derivative litigation.
For more information about the firm, please visit rosenlegal.com or contact Phillip Kim, Esq. or Deirdre Johnson at 212-686-1060 or [email protected] or [email protected].
FORWARD-LOOKING STATEMENTS: This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected composition of the settlement class, the expected size of the settlement, and the expected payment to class members. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, assumptions, and other important factors, some of which are beyond the firm’s control and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Please consult Rosen Law Firm’s ESG Report, Form ADV materials, or the securities and other reports filed by the firm with the Securities and Exchange Commission for information about these and other risks and uncertainties.
